<SEC-DOCUMENT>0001193125-18-050793.txt : 20180416
<SEC-HEADER>0001193125-18-050793.hdr.sgml : 20180416
<ACCEPTANCE-DATETIME>20180220215502
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-18-050793
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20180220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		650-489-9000

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. PORTIONS OF THIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH ASTERISKS TO DENOTE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g317356g16z36.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g317356g34n53.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;20, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Via EDGAR and Overnight Delivery </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mail Stop 4561
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549-3720 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top">Suzanne Hayes </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Assistant Director </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Office of Healthcare and Insurance </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Arcus Biosciences, Inc. </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are submitting this letter on behalf of Arcus Biosciences, Inc. (the &#147;Company&#148;), in connection with the review by the staff
(the &#147;Staff&#148;) of the Securities and Exchange Commission (the &#147;Commission&#148;) of the above-referenced Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed on February&nbsp;16, 2018 (the &#147;Registration
Statement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the commercially sensitive nature of information contained herein, this submission is accompanied by a
request for confidential treatment for selected portions of this letter. The Company has filed a separate letter with the Office of Freedom of Information and Privacy Act Operations in connection with the confidential treatment request, pursuant to
Rule 83 of the Commission&#146;s Rules on Information and Requests, 17 C.F.R. &#167; 200.83. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g05x58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this letter is to notify the Staff that, based on current market conditions,
the price range to be included on the cover of the Company&#146;s preliminary prospectus is expected to be within a range of $[***] and $[***] per share (the &#147;Price Range&#148;), resulting in a midpoint price of $[***] (the &#147;Midpoint
Price&#148;), before giving effect to a reverse stock split (the &#147;Stock Split&#148;) to be implemented prior to the initial public offering (&#147;IPO&#148;). The anticipated Price Range for this offering is based on a number of factors,
including the prevailing market conditions and estimates of the Company&#146;s business potential, the general condition of the securities market, the recent market prices of, and the demand for, publicly traded common stock of generally comparable
companies and preliminary discussions with the underwriters for the IPO regarding potential valuations of the Company. The actual bona fide price range to be included in a subsequent amendment to the Registration Statement has not yet been
determined and remains subject to adjustment based on factors outside of the Company&#146;s control. However, the Company believes that the actual bona fide price range will be within this estimated Price Range. In addition, the actual price range
to be included in such amendment will comply with the Staff&#146;s interpretation regarding the parameters of a bona fide price range. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects to reflect the Stock Split in a <FONT STYLE="white-space:nowrap">pre-effective</FONT> amendment to the Registration
Statement that includes the estimated preliminary price range; however, all dollar amounts and per share numbers in this letter are <FONT STYLE="white-space:nowrap">pre-Stock</FONT> Split, and therefore consistent with the Registration Statement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Grants and Grant Date Exercise Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of equity awards in the preceding twelve months: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Common Shares Underlying<BR>Options Granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Per Share Exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Price of Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Estimated Fair Value of Common<BR>Stock Per Share Used to Determine<BR>Stock-Based
Compensation<BR>Expense</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">3/15/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2,678,750</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">4/24/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">540,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.60</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">5/15/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">169,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">6/22/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">44,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">8/31/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">428,950</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">9/19/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">157,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$0.65</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">11/10/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">127,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1.36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">12/8/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">65,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1.36</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">1/4/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">4,440,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$2.26</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Valuation Date (As of)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair&nbsp;Value&nbsp;Per&nbsp;Share&nbsp;of<BR>Common
Stock</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;15, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.31</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.65</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.26</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation Fair Value Determinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration Statement describes the Company&#146;s use of option-pricing models for the purpose of calculating the estimated fair value of
the stock options. In the preceding twelve months, the Company&#146;s board of directors, with input from management, determined that for the purpose of granting stock options, the estimated fair value of the Company&#146;s common stock was as set
forth in the table above, after considering valuation reports from an independent third-party valuation specialist as well as other objective and subjective factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rapidly evolving prospects of the Company having only been formed on April&nbsp;30, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices, rights, preferences and privileges of the Company&#146;s convertible preferred stock relative to those of its common stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices of preferred stock sold by the Company to&nbsp;third-party&nbsp;investors in&nbsp;arms-length&nbsp;transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of marketability of the Company&#146;s common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s funding requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s product candidate pipeline; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s history and the timing of the discovery of new molecules; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the early stage of development of the Company; </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company&#146;s business given prevailing market conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the illiquidity of&nbsp;stock-based&nbsp;awards involving securities in a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market performance of comparable&nbsp;publicly-traded&nbsp;companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. and global capital market conditions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Retrospective Value Used for Financial
Reporting Purposes for March 2017 through May 2017 Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of directors granted options to purchase common
stock on March&nbsp;15, 2017, April&nbsp;24, 2017 and May&nbsp;15, 2017 to employees, with each option having an exercise price of $0.31 per share. In establishing this exercise price, the Company&#146;s board of directors considered input from
management and the previously issued valuation of the Company&#146;s common stock which was conducted as of August&nbsp;15, 2016. At the time of the grants, the Company&#146;s board of directors determined that, at the grant date, the collective
effect of the objective and subjective factors outlined above did not indicate a significant change in the fair value of the Company&#146;s common stock from the most recent prior third party valuation report. Based on these factors, the
Company&#146;s board of directors determined that the fair value of the Company&#146;s common stock on each of such grant dates was $0.31 per share. Subsequent to its option grants on May&nbsp;15, 2017, the Company
<FONT STYLE="white-space:nowrap">re-examined</FONT> whether or not the estimated fair value of its common stock associated with each grant from March&nbsp;15, 2017 to May&nbsp;15, 2017 was appropriate. The Company determined that, in retrospect, the
fair value of the common stock had increased during the first several months of 2017 as the Company advanced its research and development efforts, including the nomination of a development candidate and initiation of
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and manufacturing activities in preparation for its first clinical trials later in 2017, and therefore the value of the Company increased as a result. Accordingly, the Company has applied
a retrospective value to the stock option grants made on March&nbsp;15, 2017, April&nbsp;24, 2017 and May&nbsp;15, 2017. The Company determined that for the purposes of determining the fair value of its common stock on the date of grant for
calculating stock-based compensation expense, the appropriate fair value was $0.60 per share, and therefore the Company has used $0.60 per share to record stock-based compensation for those grants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>November 2017 and December 2017 Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company obtained a third-party valuation of its common stock as of November&nbsp;1, 2017 (the &#147;November Valuation Report&#148;), which
resulted in an estimated fair value of common stock of $1.36 per share (the &#147;November Valuation Price&#148;). The valuation performed in November 2017 involved a hybrid approach of the option pricing method and the probability-weighted expected
return method (&#147;PWERM&#148;) outlined in the American Institute of Certified Public Accountings Practice Aid, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>, also known as the Practice Aid. This valuation as
well as the objective and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subjective factors described above were considered by the board of directors in its determination of the fair value of common stock of $1.36 per share for the grant date fair value for the
options granted in November and December 2017. The Midpoint Price exceeds the November Valuation Price. The Company respectfully submits that the difference between the November Valuation Price and the Midpoint Price is primarily attributable to the
following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Feedback from potential investors following the &#147;testing the waters&#148; meetings that occurred between January&nbsp;8, 2018 through February 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The progress that has been made with the Company&#146;s programs, particularly its two most advanced programs, AB928 and AB122. AB928 is now in a Phase 1 trial in healthy volunteers and the single ascending dose portion
of the trial has been completed. To date, the drug has been safe and well tolerated and has exhibited an attractive pharmacokinetic profile. AB122 is currently in a Phase 1 trial in oncology patients and the Company is now in its second dosing
cohort. Since November 2017, the Company has also selected its lead development candidate for its CD73 program, as well identified a second dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist and a selective A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The methodology for determining the November Valuation Price incorporated multiple liquidity scenarios, not all of which allocate value to the Company&#146;s stockholders on a fully diluted, <FONT
STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. The Midpoint Price assumes with 100% probability that the Company completes an IPO, in connection with which all of the Company&#146;s convertible preferred stock will be
converted into common stock. This factor is significant because the holders of the Company&#146;s preferred stock currently enjoy substantial economic rights and preferences over the holders of the Company&#146;s common stock, including (i)&nbsp;the
right to receive dividends prior to any dividends declared or paid on any shares of the Company&#146;s common stock and (ii)&nbsp;liquidation payments in preference to holders of the Company&#146;s common stock. The corresponding elimination of the
preferences and rights enjoyed by the holders of such preferred stock upon completion of the IPO results in a higher valuation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Price Range represents a future price for shares of the Company&#146;s common stock that, if issued in the IPO, will be immediately freely tradable in a public market, whereas the November Valuation Price represents
a contemporaneous estimate of the fair value of shares that were then illiquid, might never become liquid and, even if an IPO were successfully completed, would remain illiquid at least until the expiration of the
<FONT STYLE="white-space:nowrap">180-day</FONT> lockup period following the IPO. Accordingly, there was a discount for lack of marketability applied to the fair value of the common stock in the November Valuation Price. This application of an
illiquidity discount accounts for a substantial portion of the difference between the November Valuation Price and the Midpoint Price. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The November valuation report utilized a quantitative methodology to determine the fair value of the Company&#146;s common stock, which may differ from the more qualitative and subjective methodology used by some public
market investors to determine the price they are willing to pay in the IPO. </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s consideration of various objective and subjective factors in the previous
fair value determinations, as described above, were not applicable to the current estimated Price Range. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Retrospective Value Used
for Financial Reporting Purposes for January 2018 Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In early January 2018, the Company granted options to its employees with
each option having an exercise price of $1.36 per share. In establishing this exercise price, the Company&#146;s board of directors considered input from management and the previously issued November Valuation Report. At the time of the grants, the
Company&#146;s board of directors determined that, at the grant date, the collective effect of the objective and subjective factors outlined above did not indicate a significant change in the fair value of the Company&#146;s common stock from the
most recent third party valuation report. Specifically, the Company&#146;s board of director considered the early stages of its IPO preparations, the fact it had yet to conduct any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">testing-the-waters</FONT></FONT> meetings to understand investor interest in the IPO and uncertain market conditions driven by the then current political and economic climate. Based
on these factors, the Company&#146;s board of directors determined that the fair value of the Company&#146;s common stock on each of such grant dates was $1.36 per share. Subsequently, upon receipt of the February 2018 valuation report valuing the
common stock at $2.26 per share, the Company evaluated whether or not, in retrospect, the value of the common stock on January&nbsp;4, 2018 was appropriate. The Company determined that, in retrospect, the fair value of the common stock had increased
between the Company&#146;s initial confidential submission of its Form <FONT STYLE="white-space:nowrap">S-1</FONT> on December&nbsp;15, 2017 and January 2018 due in part to the milestone of submitting the <FONT STYLE="white-space:nowrap">S-1</FONT>
to the SEC and additional advances in the Company&#146;s research and development efforts. The Company determined that for the purposes of determining the fair value of its common stock on the date of grant for calculating stock-based compensation
expense, the appropriate fair value was $2.26 per share (&#147;Retrospective January Value&#148;), and therefore the Company intends to use $2.26 per share to record stock-based compensation for those grants in its financial result for the first
quarter of 2018. The Company notes that the Retrospective January Value differs from the Midpoint Price due to the factors noted about under the subsection &#147;<I>November 2017 and December 2017 Option Grants.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will set forth a bona fide offering price range consistent with Commission guidance in a
<FONT STYLE="white-space:nowrap">pre-effective</FONT> amendment to the Registration Statement prior to the distribution of any preliminary prospectus and commencement of the Company&#146;s road show process, which it anticipates could commence as
soon as <U>March</U><U></U><U>&nbsp;5, 2018</U>. The bona fide offering price range will be narrower than, but is expected to be within, the Price Range stated above, and the parameters of that price range will be subject to then-current market
conditions, continuing discussions with the underwriters, as well as further business, market and other developments affecting the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************************* </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 20, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page&nbsp;
 7
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please contact the undersigned at (650) <FONT STYLE="white-space:nowrap">463-5381</FONT> or
hmayon@gunder.com if you have any questions with respect to this letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Heidi E. Mayon, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Heidi E. Mayon, Esq. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Confidential Material Redacted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED BY ARCUS BIOSCIENCES, INC. </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g317356g05x58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g05x58.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  : 6(# 2(  A$! Q$!_\0
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M=_IU-3Z5>/J&F074D8C:5=VT-N _&K,L4<Z%)8UD0]589'Y4J(L:!$4*JC
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MN1D+T]/SJA+K%_"D()W9M'D,JH&1GQG.X<<>W!S72%5/! (^E 4     =.*
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3EVCT'7/3O2& Y SUHI:*8C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g317356g16z36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g16z36.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  < .<# 2(  A$! Q$!_\0
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g317356g34n53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g34n53.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !; $X# 2(  A$! Q$!_\0
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M4=*DL[B5-.\M76-GC\A,S"0X7H<')['\:W2,@CUK"M/#'V6SDA6Y0,5B"-'
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6>1/-D$3N<ED#D*<GKQCGO6C10!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
